Posted by Michael Wonder on 25 Jul 2022
HLS announces that Vascepa is now reimbursed by Ontario's Provincial Drug Plan
25 July 2022 - Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in label.
HLS Therapeutics announces that it has entered into a product listing agreement with Ontario, for the listing and public reimbursement of Vascepa (icosapent ethyl) on the province's Public Prescription Drug Insurance Plan.
